LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

Participants can access the conference call live via webcast on the Events page of the Company’s website at . Participants who wish to ask a question may to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website. 

About Lexicon Pharmaceuticals 

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit . 

For Investor and Media Inquiries: 

Lisa DeFrancesco  

Lexicon Pharmaceuticals, Inc. 

 



EN
23/07/2025

Underlying

LXRXLexicon Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lexicon Pharmaceuticals Inc.

 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavap...

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic ...

September 11, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S...

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced that the Company has submitted additional clini...

September 8, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin...

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the relevance of inhibiting pilavapadin’s novel target, AAK1, ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral ...

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada. Presentation details: Poster #53: ...

September 3, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Fai...

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch